Abstract Library

#4458 Survival and optimal follow-up cut-off of lung neuroendocrine tumours after surgery: Experience of a high-volume centre over 25 years

Introduction: Surgery is the curative therapy for lung neuroendocrine tumours (NET). Follow-up protocols after surgery are not evidence based and factors affecting survival are not clear.

Conference:

Presenting Author: Mortagy M

Authors: Mortagy M, El Asmar M, Nonaka D, Dolly S, Srirajaskanthan R,

Keywords: Lung NET, Lung NET Surgery, Follow-up after surgery,

#4439 Survival of 10,418 lung neuroendocrine tumours after surgical resection: Who needs follow-up and for how long?

Introduction: Surgical resection is the primary treatment for lung neuroendocrine tumours (NETs). The optimal follow-up period is debated in these patients.

Conference:

Presenting Author: El Asmar M

Authors: El Asmar M, Mortagy M, Chandrakumaran K, Ramage J,

Keywords: Lung, Neuroendocrine tumour, survival, surgery, follow-up period,

#3206 Efficacy and safety of peptide receptor radionuclide therapy (PRRT) in patients with chronic kidney disease (CKD)

Introduction: The kidney is a dose-limiting organ in PRRT. Most clinical studies have focused on the safety of PRRT with normal or mildly impaired kidney function.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Alsadik S, Gnanasegaran G, Chen L, Toumpanakis C, Caplin M,

Keywords: neuroendocrine tumor, peptide receptor radionuclide therapy PRRT, 177lu-DOTATATE, chronic kidney disease,

#2068 Durvalumab plus Tremelimumab for the Treatment of Patients (pts) with Advanced Neuroendocrine Neoplasms (NENs) of Lung or Gastroenteropancreatic (GEP) Origin. A Phase II Multicohort Trial (DUNE Trial / GETNE 1601)

Introduction: Immuno check-point inhibitors development in grade 1-2 NENs is limited by low mutation tumor load and PD-1/PDL-1 expression. The combination of an PDL-1 and CTLA-4 inhibitors could increase the probability of success in this setting. In high grade NENs the rational for immunotherapy is stronger based on experiences in small cell lung cancer.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Hernando-Cubero J

Authors: Hernando-Cubero J, Manzano J, Benavent M, Lopez C, Teulé R,

Keywords: Durvalumab, Tremelimumab, Neuroendocrine, Immunotherapy,

#1392 How Long Should We Look Up for Recurrence After Resection of Pancreatic Neuroendocrine Tumors?

Introduction: There remains several unsolved issues to be settled about the management of pancreatic neuroendocrine tumors (PNETs) after resection. One of these problems are the follow up period after a complete resection of the tumor.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Sato A, Masui T, Nakano K, Kawaguchi Y, Takaori K,

Keywords: Pancreatic neuroendocrine tumor, enucleation, follow-up period,